Download UK Oncology Forum 2016

UK Oncology Forum 2016
Thursday 16th June & Friday 17th June 2016
Beaumont House, Windsor
FACULTY
CHAIR - PROFESSOR RUTH PLUMMER
Clinical Professor of Experimental Cancer Medicine, Northern Institute for Cancer Research, Newcastle University
VICE CHAIR - PROFESSOR DANIEL HOCHHAUSER
Kathleen Ferrier Chair of Medical Oncology and Consultant Medical Oncologist at UCL Cancer Institute/UCLH Trust
DR RICHARD ADAMS
Clinical Reader of Oncology & Palliative Medicine, Cardiff University School of Medicine
PROFESSOR AMIT BAHL
Consultant Clinical Oncologist and Clinical Director, Bristol Haematology and Oncology Centre
DR MARTIN EATOCK
Consultant/Honorary Senior Lecturer in Medical Oncology, Medical Director, Northern Ireland Cancer Network
The programme has been designed and developed solely by the Oncology Forum Faculty. No sponsors have any input or influence over the programme.
This meeting is for UK Oncology Healthcare Professionals only. The meeting will run strictly in accordance to the ABPI Code of Practice.
The varying sponsorships packages are primarily for the purchase of promotional exhibition stand space.
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
Dear Colleagues
On behalf of the UK Oncology Forum Faculty, I am delighted to warmly welcome you all to the Tenth 2016 UK Oncology Forum,
here in Windsor.
This year sees the UK Oncology Forum celebrate its tenth year! The faculty are delighted that this special milestone has been
rewarded by a significant increase in the number of delegates, speakers and sponsors.
At the “Oncology Forum Faculty 2016 Kick Off” meeting last year, we decided that we had been overly ambitious by running the
repeated clinical break-out session all in one day at the 2015 meeting. This year we have split the session over two days and
expanded the length of the meeting. We initially thought that this might have had an impact on reduced attendance, however
we were wrong to have concerns. This year sees the meeting smash all previous records and has resulted in 2016 having a
considerable waiting list.
As always we listened to your invaluable feedback from 2015.
Last year we introduced pathology and personalised medicine elements in to all of the clinical breakout sessions. This was a
resounding success. With this positive feedback, we decided that we would introduce a whole individual session dedicated to
the “Practical Delivery of Personalised Medicine”. Professor Manuel Tellez Salto has kindly agreed to be the session chair and has
designed and produced an excellent programme which includes some the leading UK Oncology cancer pathologists contributing
to a first class clinical session.
The UK Oncology Forum has now become an invaluable, educational “must attend” meeting within the UK calendar of oncology
meetings. Its combination of topics ranging from NHS policy and funding to the future of oncology treatments and research make
the meeting a huge draw to the UK NHS cancer healthcare community.
As in previous year’s, I would like to reiterate that this educational meeting belongs to you. We can only improve the programme
by listening to your opinions and suggestions. Please will you support us by completing the evaluation forms at the end of each
session? We use these insights and intelligence to tailor the 2017 programme to meet the needs of your professional development
and clinical practice.
We wanted to celebrate our special birthday by setting an objective of recruiting two dynamic keynote speakers. We hope that
you will agree that we have been successful in achieving this goal! I would like to take this opportunity to warmly congratulate
Professor Nazreen Rahman, who opens the 2016 meeting on being awarded a CBE for services to medical science.
We are thrilled to welcome Professor Anthony Zietman, all the way from the USA to close the tenth UK Oncology Forum. Anthony
is also a member of the Radiotherapy clinical session team, chaired by Professor David Sebag-Montefiore. David has crafted a first
class session with a truly international flavour!
This year’s Question Time session has a dynamic and knowledgeable panel chaired by broadcaster and journalist Peter Sissons. As
always, the questions aim to cover both challenging and controversial issues which face all of us in these testing times.
With the 2016 Oncology Forum expanding and flourishing it promises to be as stimulating, worthwhile, interactive and as
provocative as ever! Of course none of this would be possible without the ongoing and unwavering support of the Faculty, the
input and commitment of all the session chairs and speakers, your time and engagement in the sessions and last, but not least, the
generous non-restricted educational grants from industry.
We would like to especially thank Healthcare at Home and all our other supporters for their commitment to this special meeting.
Please share your appreciation of the Industry support by visiting the exhibition area during the breaks.
Thank you for taking the time to attend the UK Oncology Forum and for your contributions to the sessions.
I look forward, as I’m sure you do, to a highly enjoyable, educational, engaging and challenging two days.
Kind regards
Professor Ruth Plummer
Clinical Professor of Experimental Cancer Medicine, Northern Institute
for Cancer Research, Newcastle University
Chair UK Oncology Forum
TIMINGS
Thursday 16th June 2016
12:00hrs
Arrival, registration, buffet lunch and Exhibition
13:00hrs
Welcome and Opening Keynote Speaker Professor Nazneen Rahman
14:15hrs
Clinical Sessions (Day 1)
17:30hrs
Question Time
18:45hrs
Meeting concludes
20:00hrs
Conference dinner (meet in exhibition area from 19:30hrs for networking)
Friday 17th June 2016
08:30hrs
Main plenary
08:45hrs
Clinical Sessions (Day 2)
10:00hrs ~
11:00hrs
Helping industry to make the most of twitter at healthcare events (optional
complimentary workshop for our industry colleagues)
11:45hrs
Clinical Sessions (Day 2) close
12:00hrs
Closing Keynote Speaker - Professor Anthony Zietman
13:00hrs
Lunch
13:15hrs ~
13:45hrs
(Optional workshop) Helping clinicians to make the most of twitter at
healthcare events
13:30hrs
(onwards)
Departures (please see departure boards for train and airport shuttles)
The programme has been designed and developed solely by the Oncology Forum Faculty. No sponsors have any input or influence over the programme.
This meeting is for UK Oncology Healthcare Professionals only. The meeting will run strictly in accordance to the ABPI Code of Practice.
The varying sponsorships packages are primarily for the purchase of promotional exhibition stand space.
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
DAY 1
OPENING KEYNOTE SPEAKER
PROFESSOR NAZNEEN RAHMAN
Head of the Division of Genetics and Epidemiology
“Should oncologists do genetic testing?”
The Institute of Cancer Research and Head of the Cancer Genetics Clinical Unit
The Royal Marsden NHS Foundation Trust
QUESTION TIME
MR PETER SISSONS
Chair of Question Time Broadcaster and Author
PROFESSOR KARL CLAXTON
Professor in the Department of Economics and Related Studies at the University of York
Senior Research Fellow in the Centre for Health Economics, University of York
PROFESSOR ANGUS DALGLEISH
Professor of Oncology, George’s University of London
DR SHELLEY DOLAN
Chief Nurse, The Royal Marsden Hospital NHS Foundation Trust and Executive Director RM Partners Accountable Cancer
Network
MR TOM HASWELL
NCRI CTRad, Screening, Prevention & Early Diagnosis Advisory Group (SPED)
PROFESSOR DANIEL HOCHHAUSER
Kathleen Ferrier Chair of Medical Oncology and Consultant Medical Oncologist at UCL Cancer Institute/UCLHTrust
DR REBECCA LUMSDEN
Head of Science Policy at the ABPI
Clinical Streams – Day 1 & Day 2
Thursday 16th June 2016 – 14:15hrs ~ 17:15hrs
Friday 17th June 2016 – 08:45hrs ~ 11:45hrs
BREAST
CHAIR - PROFESSOR PAUL ELLIS
Professor of Cancer Medicine, Guy’s Hospital & Kings College London
DR NICHOLAS TURNER (DAY ONE)
Academic Consultant Medical Oncologist
“What’s new in ER positive breast cancer - novel therapies and how do they fit into UK practice”
PROFESSOR MURRAY BRUNT (DAY ONE)
Consultant & Honorary Professor Clinical Oncology, Cancer Centre, Royal Stoke University Hospital & Keele University
Hot and current breast radiotherapy topic “Nodal radiotherapy and hypofractionation – including
ESTRO breast radiotherapy consensus guidelines”
DR MICHELLE KOHN (DAY ONE)
Specialist in Supportive Cancer Care and in late 2009, she joined LOC to set up a cancer ‘survivorship’ service, launched
in early 2010 as the Living Well Programme
“Living Well for a Good Survival”
PROFESSOR PETER SCHMID (DAY TWO)
Queen Mary University of London, Barts Cancer Institute
“What’s new in TNBC - is there any role for immune checkpoint inhibitor therapy?”#
DR DUNCAN WHEATLEY (DAY TWO)
Medical Doctor, Director of Research in Cornwall , Clinical Lead for Cancer Research SW Peninsula
Hot and current breast radiotherapy topic “Nodal radiotherapy and hypofractionation - including
ESTRO breast radiotherapy consensus guidelines”
DR MICHELLE KOHN (DAY TWO)
Specialist in Supportive Cancer Care and in late 2009, she joined LOC to set up a cancer ‘survivorship’ service, launched
in early 2010 as the Living Well Programme
“Living Well for a Good Survival”
The programme has been designed and developed solely by the Oncology Forum Faculty. No sponsors have any input or influence over the programme.
This meeting is for UK Oncology Healthcare Professionals only. The meeting will run strictly in accordance to the ABPI Code of Practice.
The varying sponsorships packages are primarily for the purchase of promotional exhibition stand space.
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
PRACTICAL DELIVERY OF PERSONALISED MEDICINE
CHAIR – PROFESSOR MANUEL SALTO TELLEZ
Clinical Professor, Queens University Belfast, Centre for Cancer Research and Cell Biology
PROFESSOR MANUEL SALTO TELLEZ
Clinical Professor, Queens University Belfast, Centre for Cancer Research and Cell Biology
“Next generation sequencing - clinical research, clinical trials and routine diagnostics”
PROFESSOR RICHARD KENNEDY
Professor of Medical Oncology, Queens University Belfast
“Gene expression arrays and molecular diagnostics”
DR RACHEL BUTLER
Consultant Clinical Scientist, Cardiff & Vale NHS Trust
“Baseline single-gene testing in oncology”, and a practical review to oncologists of RAS, BRAF,
EGFR, ALK and other tests. PROFESSOR GARETH THOMAS
Professor of Experimental Pathology, University of Southampton
“Practical Cancer Immunology testing”
DELIVERING CARE TO THE UK NHS CANCER PATIENT
“EXPERT CANCER NURSING AND ITS IMPACT ON PATIENT / FAMILY CARE AND OUTCOMES”
This session will focus on the expertise of nursing both in terms of research and clinical care and the impact it has on the
delivery of care and impact on outcomes for the person with cancer and their family. Our nursing experts are drawn from
across the UK and lead on cancer research, care and innovation in services. Please join us for an exciting session that
places the person with cancer at the heart of our services.
CHAIR DR SHELLEY DOLAN
Chief Nurse, The Royal Marsden Hospital NHS Foundation Trust and Executive Director RM Partners Accountable Cancer
Network
DR NATALIE PATTISON
Senior Clinical Nursing Research Fellow/Trust Lead for User Involvement in Research, The Royal Marsden NHS FT
“Precision nursing, a way to ensure personalised cancer care?”
PROFESSOR MARY WELLS
Professor of Cancer Nursing Research & Practice, Stirling University
“Nursing contribution to improving experiences and outcomes after treatment”
DR CAROLE FARRELL
Nurse & AHP Research Fellow, The Christie NHS FT
“The impact of chemotherapy on patients over 65 years”
MRS NETTY KINSELLA
Uro-oncology nurse consultant, The Royal Marsden
“Improving patient experience through stratification of the prostate cancer pathway”
LOWER GI CANCER SESSION
“NEW DEVELOPMENTS IN THE MULTIPLE MODALITIES INVOLVED IN MANAGING COLORECTAL
CANCER AND PERITONEAL MALIGNANCIES”
In the era of personalised medicine, immunotherapy and multiple ‘omics’ in diagnosis, prognostication and prediction of
treatment benefit, many other advances are being made in lower GI cancer. This wide-ranging session ranges from the
repurposing of a very old drug to the evidence for and against systemic therapy following combination chemoradiotherapy
and surgery in rectal cancer. It includes updates in the management of malignancies in the peritoneal cavity from one of our
UK supra-regional centres and the current state of the art and the future promise of stereotactic radiotherapy for colorectal
cancer. Finally, it explores the multiple possible roles for exercise in prevention, prehabilitation before surgery, and its use to
potentially improve survival and quality of life in both early and advanced colorectal cancer. Breaking news from the ASCO
Annual Meeting earlier this month will also be discussed.
CHAIR - PROFESSOR RICHARD WILSON
Clinical Professor, School of Medicine, Dentistry and Biomedical Sciences, Queen University Belfast
PROFESSOR SIR JOHN BURN
Professor of Clinical Genetics, Newcastle University, Chair Genetics Specialty Group, National Institute of Health Research,
Director of the Collaborative Group of Genetics in Healthcare (NIHR and Dept of Health)
“Aspirin Zsar”
DR RICHARD ADAMS
Velindre Hospital, Cardiff
“Controversies around adjuvant therapy following chemoradiotherapy for rectal cancer”
PROFESSOR ANDREW G RENEHAN PHD FRCS
Professor of Cancer Studies and Surgery, The Christie NHS Foundation Trust, Faculty Institute of Cancer Sciences, University
of Manchester, Manchester Academic Health Science Centre
“Surgery for Peritoneal Malignancies”
DR MARK HARRISON
Mount Vernon Hospital.
“Stereotactic body radiotherapy in colorectal cancer”
DR VICKY COYLE
Belfast City Hospital
“Exercise in the management of colorectal cancer”
The programme has been designed and developed solely by the Oncology Forum Faculty. No sponsors have any input or influence over the programme.
This meeting is for UK Oncology Healthcare Professionals only. The meeting will run strictly in accordance to the ABPI Code of Practice.
The varying sponsorships packages are primarily for the purchase of promotional exhibition stand space.
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
LUNG & MELANOMA SESSION
“OPTIMISING CHANCE OF CURE OR QUALITY LONG TERM SURVIVAL
IN MELANOMA AND LUNG CANCER”
It is worth restating that whereas oncologists and others specialising in lung cancer and melanoma were previously pitied
by their peers treating tumours with better outcomes, the fantastic progress in detailed diagnosis and specific therapy has
revolutionised life for patients and clinicians alike. Most patients with melanoma are diagnosed early and cured, and
now even those with advanced disease may enjoy prolonged survival thanks to immunotherapy. Surgery is still offers the
best chance of cure for lung cancer, and the huge body of clinical evidence evaluating the risk of relapse has informed
the new staging system. How can we maximise treatment benefit and minimise toxicity in these tumour types to build on
recent successes? These vital questions will be addressed by our distinguished speakers and vigorous discussion will be
encouraged!
CHAIR ~ DR MARIANNE NICOLSON
Consultant Medical Oncologist and Honorary Senior Lecturer to NHS Grampian
PROFESSOR PETER GOLDSTRAW
Emeritus Professor of Thoracic Surgery, National Heart and Lung Institute, Imperial College, Honorary Consultant in Thoracic
Surgery, Royal Brompton Hospital, London
Past President, International Association for the Study of Lung Cancer
“IASLC staging surgical data”
PROFESSOR KEITH KERR
Aberdeen Royal Infirmary
“The Pathology of Patient Pathology”
DR PAUL NATHAN
Mount Vernon Hospital
“Side-effect management of immunotherapy”
PROSTATE
CHAIR – PROFESSOR AMIT BAHL
Consultant Clinical Oncologist, Bristol Haematology and Oncology Centre
PROFESSOR NOEL CLARKE (DAY ONE)
The Christie NHS Foundation Trust, Manchester
“Lessons from National Prostate Cancer Audit”
PROFESSOR JOHANN DE BONO (DAY ONE)
The Institute of Cancer Research, London
“Advances in managing metastatic prostate cancer with particular emphasis on genomics”
DR NICK VAN AS (DAY TWO)
Medical Director of The Royal Marsden and Consultant Clinical Oncologist in Urology
“Oligometastatic Disease”
PROFESSOR JOHANN DE BONO (DAY TWO)
The Institute of Cancer Research, London
“Advances in managing metastatic prostate cancer with particular emphasis on genomics”
RADIOTHERAPY
“THE TECHNICAL RADIOTHERAPY REVOLUTION AND FUTURE CHALLENGES”
Rapid changes are happening in the field of technical radiotherapy with the increasing availability of stereotactic ablative
radiotherapy (SABR), the MR linear accelerator and proton beam therapy. Within the next five years patients in the UK will
be treated with all of these approaches for a range of indications, some in the research setting. This session will highlight
experience with these new approaches, discuss the new approaches and the evidence for patient benefit. It will also
highlight the clinical areas of research interest and the need for future innovative clinical studies.
CHAIR - PROFESSOR DAVID SEBAG-MONTEFIORE
Professor of Clinical Oncology University of Leeds
DR KEVIN FRANKS
Leeds Cancer Centre and University of Leeds
“Stereotactic Ablative Radiotherapy (SABR) – Current and future indications”
DR ALISON TREE
Royal Marsden Hospital and Institute of Cancer Research
“MR Linear Accelerator radiotherapy – what will if offer and who should we treat?”
PROFESSOR ANTHONY ZIETMAN
Massachusetts General Hospital and Harvard Medical School
“Proton beam therapy – the good and the bad: a US perspective”
PROFESSOR DAVID SEBAG-MONTEFIORE
University of Leeds and Leeds Cancer Centre
“Innovative Radiotherapy Clinical Trials design”
The programme has been designed and developed solely by the Oncology Forum Faculty. No sponsors have any input or influence over the programme.
This meeting is for UK Oncology Healthcare Professionals only. The meeting will run strictly in accordance to the ABPI Code of Practice.
The varying sponsorships packages are primarily for the purchase of promotional exhibition stand space.
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
UPPER GI
“PRACTICAL MANAGEMENT OF LOCALISED OESOPHAGEAL CANCER
IN THE 21ST CENTURY”
Despite recent advances in surgical techniques and the development of more sophisticated techniques for the delivery
of radiotherapy, the outcome for oesophageal cancer remains poor. This session aims to explore some of these recent
developments and highlight how these may be applied in routine practice. It will also look at how better understanding
of the “biology” of oesophageal cancer and its’ application to clinical trial design, may lead to improvements in patient
management.
CHAIR - DR MARTIN EATOCK (DAY ONE & DAY TWO)
Consultant/Honorary Senior Lecturer in Medical Oncology, Medical Director,
Northern Ireland Cancer Network
MR JAMES GOSSAGE (DAY ONE)
Consultant General Surgeon, Guy’s & St Thomas’ NHS Foundation Trust
“Surgery for Oesophageal cancer in the 21st Century: Current practice and future developments”
Debate: This house believes that the optimal neoadjuvant treatment for operable oesopahageal
adenocarcinoma is with chemo-radiotherapy
Proposer: DR SOMNATH MUKHERJEE
Clinical Oncologist, University of Oxford
Opposer: DR STEPHEN FALK
Clinical Oncologist, University Hospitals, Bristol
DR RICHARD TURKINGTON (DAY ONE)
Senior Lecturer in Medical Oncology, Queens University Belfast
“The future role of personalised medicine in operable oesophageal cancer”
MR JAMES GOSSAGE, DR STEPHEN FALK, DR RICHARD TURKINGTON (DAY ONE)
Case Discussions – virtual MDT
MR ANDREW DAVIES (DAY TWO)
Consultant Upper GI surgeon at Guy’s and St Thomas’ NHS Foundation Trust
“Surgery for Oesophageal cancer in the 21st Century: Current practice and future developments”
DEBATE: This house believes that the optimal neoadjuvant treatment for operable oesopahageal
adenocarcinoma is with chemo-radiotherapy
Proposer: DR SOMNATH MUKHERJEE Opposer: DR STEPHEN FALK
Clinical Oncologist, University of Oxford
Clinical Oncologist, University Hospitals, Bristol
DR RICHARD TURKINGTON (DAY TWO)
Senior Lecturer in Medical Oncology, Queens University Belfast
“The future role of personalised medicine in operable oesophageal cancer”
MR ANDREW DAVIES, DR STEPHEN FALK, DR RICHARD TURKINGTON (DAY TWO)
Case Discussions – virtual MDT
DAY 2
INTERNATIONAL CLOSING KEYNOTE SPEAKER
PROFESSOR ANTHONY ZIETMAN
Editor in chief of the Red Journal IJROBP. Massachusetts General Hospital, USA
“Beams, Dreams and Proton schemes - how the UK can avoid the mistakes of US cancer care”
Optional Workshops
Friday 17th June 2016
WORKSHOP 1 (in the Hanover)
Helping industry to make the most of twitter at healthcare events
10:00hrs ~ 11:00hrs
THIS WORKSHOP IS FOR INDUSTRY SPONSOR ONLY
· What›s the value of twitter? · How it works - hash tags, influencers and topics · What good content looks like · The digital exchange - Examples of pharma / HCP engagement · Measuring success · Compliance
WORKSHOP 2 (in the Beaumont)
Helping clinicians to make the most of twitter at healthcare events
13:15hrs ~ 14:15hrs OPTIONAL FOR HEALTHCARE PROFESSIONALS
· What›s the value of twitter? · How to get started · Who else is doing it and who should I follow? · Listening versus proactively posting content · Examples of good content to share
The programme has been designed and developed solely by the Oncology Forum Faculty. No sponsors have any input or influence over the programme.
This meeting is for UK Oncology Healthcare Professionals only. The meeting will run strictly in accordance to the ABPI Code of Practice.
The varying sponsorships packages are primarily for the purchase of promotional exhibition stand space.
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
SPONSORS
GOLD SPONSOR
SILVER SPONSORS
BRONZE SPONSORS
Travel & accommodation will be supplied in accordance with ABPI codes of practice
Accreditation points have been applied for:-
ENDORSED BY UKONS
The programme has been designed and developed solely by the Oncology Forum Faculty. No sponsors have any input or influence over the programme.
This meeting is for UK Oncology Healthcare Professionals only. The meeting will run strictly in accordance to the ABPI Code of Practice.
The varying sponsorships packages are primarily for the purchase of promotional exhibition stand space.
THE FACULTY
Professor Ruth Plummer, Chair
Clinical Professor of Experimental Cancer Medicine, Northern Institute for Cancer
Research, Newcastle University
Ruth Plummer is Professor of Experimental Cancer Medicine at the Northern Institute for Cancer Research, Newcastle
University and an honorary consultant medical oncologist in Newcastle Hospitals Foundation Trust. She is Director of the
Sir Bobby Robson Cancer Trials Research Centre within the Northern Centre for Cancer Care which is a dedicated clinical
trials unit based within the regional cancer centre. She leads the Newcastle Experimental Cancer Medicine Centre and
also the CRUK Newcastle Cancer Centre. She trained at Cambridge and Oxford before moving back home to Newcastle
and settling with her family in the Tyne valley. Her research interests are in the field of DNA repair and early phase clinical trials of novel agents or novel imaging targets.
She developed the clinical pharmacodynamic assay used in the first-in-class PARP inhibitor trial in 2003, and has worked
with many of the PARP inhibitors currently under clinical development. Her pre-clinical research is focussed on targeting
other elements of the DNA repair pathways, and taking such agents into clinical trials. Professor Daniel Hochhauser, Vice Chair
Chair of Medical Oncology and Consultant Medical Oncologist at UCL Cancer Institute/
UCLH Trust
Professor Hochhauser qualified in medicine from Cambridge and the Royal Free Hospital Medical School in 1983.
Following postgraduate medical training in London and Oxford he was appointed clinical fellow in medical oncology at
the Institute of Molecular Medicine, Oxford where he completed a DPhil. He subsequently worked as a medical oncology
fellow at Memorial Sloan Kettering Cancer Center New York before appointment as a senior Lecturer and consultant in
1996.
Professor Hochhausers major clinical interest is in gastrointestinal medical oncology. His research is focused on
development of novel therapeutics and early phase clinical studies.
Dr Richard Adams
Clinical Reader of Oncology & Palliative Medicine, Cardiff University School of
Medicine
Richard Adams is a reader and Director of the Wales Cancer Trials Unit and Wales Cancer Bank. His clinical practice
and research is focused on lower gastrointestinal cancers. He is chair of the NCRI anorectal subgroup and is active in
national and international research organisations including IRCI the International Rare Cancer Initiative (for anal cancer)
and ARCAD.
He chairs the biomarker development group for FOCUS4 is Chief investigator for FOCUS4 D and leads on the
radiotherapy quality assurance for the UK ARISTOTLE, COPERNICUS and TREC trials. He oversees collaborative
translational research in numerous phase II/ III colorectal cancer trials. He was a founder member of and now chairs the
South Wales Cancer Care link with Sierra Leone.
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
THE FACULTY
Professor Amit Bahl
Consultant Clinical Oncologist and Clinical Director, Bristol Haematology and Oncology
Centre
Amit Bahl is Consultant Clinical Oncologist and Clinical Director at Bristol Haematology & Oncology Centre with a special
interest in breast and urological cancers. He is the research lead for Bristol Haematology and Oncology Centre. He has
led and developed the prostate brachytherapy service at Bristol. He has been an expert adviser to NICE for the technology
appraisal on new drugs and an external service reviewer at oncology departments elsewhere in the country. Prior to his
current roles, Dr Bahl became Member of the Royal College of Physicians (UK) and trained in Clinical Oncology, achieving
the Fellowship of the Royal College of Radiologists qualification. He has been awarded the fellowship of the Royal College
of Physicians. He is a current member of the National Cancer Research Institute Clinical Studies Groups for prostate and
bladder cancer, college tutor of the Royal College of Radiologists and has supervised several MD theses in breast and
prostate cancer research. He has previously been in the NCRI Renal clinical studies group. He is an Executive Committee
member of the British Uro-oncology group. Dr Bahl is actively involved in research into breast, prostate and bladder
cancers, participates in clinical trials locally and nationally and regularly publishes articles in these research areas and has
several presentations at national and international meetings. In 2012, Dr Bahl was awarded the Cochrane Shanks Jalil
Professorship by the Royal College of Radiologists, London.
Dr Martin Eatock
Consultant/Honorary Senior Lecturer in Medical Oncology, Medical Director, Northern
Ireland Cancer Network
Dr Eatock qualified in medicine from the University of Edinburgh and trained in Oncology in Manchester and Glasgow.
He took up post as a Consultant and Honorary Senior Lecturer in Medical Oncology in Belfast in 2000 and is an active
member of the Upper Gastro-intestinal, Hepato-pancreatobiliary and Neuro-endocrine tumour teams. He has clinical
and research interests in gastro-intestinal cancer and drug development and is currently chief investigator for a number
of national and international clinical trials in upper GI malignancy. Dr Eatock was appointed as Medical Director to the
Northern Ireland Cancer Network in 2012 and has overseen the re-development of the Network since then with an
expansion in the network site specific groups and the introduction of Peer Review of Cancer MDTs in Northern Ireland.
OPENING KEYNOTE SPEAKER
Professor Nazneen Rahman
Professor of Human Genetics at the Institute of Cancer Research
Should oncologists do genetic testing?
Head of the Division of Genetics and Epidemiology The institute of Cancer Research and Head of the Cancer Genetics
Clinical Unit The Royal Marsden NHS Foundation Trust Nazneen Rahman is Professor of Human Genetics at the Institute of
Cancer Research (ICR) and Head of Division of Genetics & Epidemiology. She is also a Consultant Clinical Geneticist and
Head of Cancer Genetics at The Royal Marsden. She qualified in medicine at Oxford University in 1991 and undertook
her general medical training in London. She obtained a PhD in Molecular Genetics at ICR in 1999 and her Certificate
of Completion of Specialist Training in Clinical Genetics in 2001. Her research work has been directed towards the
mapping and identification of human disease genes using genome-wide linkage analysis, positional cloning, candidate
gene resequencing and genome-wide association analyses. She has identified 6 breast / ovarian cancer predisposition
genes (CHEK2, BRIP1, ATM, PALB2, RAD51D and PPM1D), 4 childhood cancer / overgrowth predisposition genes
(BUB1B, PALB2, CEP57, EHZ2) and multiple common variants for breast cancer, Wilms tumor and testicular cancer though
GWAS. She also has a strong commitment to translation of research findings, using gene identification data to clarify
the prevalence and risks of mutations and to produce diagnostic and management guidance for rare cancer-associated
conditions. Nazneen is currently leading the Mainstreaming Cancer Genetics programme a national translational research
programme which aims to introduce germline genetic testing of cancer genes into routine cancer patient care. Nazneen
has an increasing participation in public engagement including television, radio and newspaper interviews, writing a blog
– “Harvesting the Genome” – and using social media to engage with both the wider scientific community as well as the
general public. She recently collaborated with a playwright on a theatre piece exploring the role of genetic inheritance in
human health. Nazneen was included in the 2014 BBC Woman’s Hour Power List of Game Changers. In addition to all
her clinical and scientific activity, Nazneen is also a singer/songwriter and has released her first album in 2014.
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
QUESTION TIME SESSION
Mr Peter Sissons,Chair
Chair of QuestionTime, Broadcaster and Author
Peter’s awards include being named by the Broadcasting Press Guild as the “Best Front of Camera Performer” in 1984,
and the Royal Television Society’s prestigious “Judges Award” for his work on the Channel Four News - seven years in
which it won an unprecedented 3 consecutive BAFTA awards In June 1989, Peter took over from Sir Robin Day as the
presenter of Question Time. He continued until December 1993, when he was followed by David Dimbleby. He also copresented BBC’s 1992 General Election Night coverage with David Dimbleby and Peter Snow. Previously he had been
a co-presenter on ITN’s election night programmes in 1983 and in 1987. He has worked for ITN, Channel 4 News and
BBC News, where he hosted the BBC Nine O’Clock News and the Ten O’Clock News. He retired from this position in
January 2003. Peter reportedly accused the BBC of ageism in response to its decision to move him from the prime slot.
Professor Karl Claxton
Professor in the Department of Economics and Related Studies at the University of York
Senior Research Fellow in the Centre for Health Economics, University of York
Karl Claxton is a Professor in the Department of Economics and the Centre for Health Economics at the University of
York. He leads the economic evaluation component of the Health Economics MSc at the University of York. He is a past
co-editor of the Journal of Health Economics and for many years held an adjunct appointment at the Harvard School of
Public Health. His expertise spans economic evaluation, Bayesian decision theory and health policy and has authored
textbooks on economic evaluation and decision modelling. He was a founding member of the NICE Technology Appraisal
Committee and continues to contribute to the development of the NICE Guide to the Methods of Technology Appraisal.
He has contributed in a number of ways to recent policy debates such as pharmaceutical pricing and innovation. A well
as NICE he has also advised, Department of Health, HM Treasury, Department of Business Innovation and Skills and the
Office of Life Sciences.
Dr Shelley Dolan
Chief Nurse / Director of Infection Prevention & Control Nursing, Risk and Quality The
Royal Marsden Hospital
Shelley Dolan has worked in critical care and in cancer since 1990. In 2000 Shelley was the first Nurse Consultant
in Cancer: Critical Care to be appointed in the UK. In June 2007 Shelley was appointed as Chief Nurse of The Royal
Marsden NHS Foundation Trust and in 2015 as Executive Director of the Cancer Vanguard in West London with
colleagues from UCLH and The Christie. Shelley has chaired a London Research Ethics committee for the last 10 years and
is the co-chair of the AUKUH Clinical Academic Careers Group.
Mr Tom Haswell
NCRI CTRad, Screening, Prevention & Early Diagnosis Advisory Group (SPED)
Tom’s background was in engineering and he worked overseas for many years. In 1993 at an employment medical in
Jeddah, Saudi Arabia he was told he had lung cancer. He returned home to Glasgow, underwent further tests only to be
told there was no treatment which would have any effect on his lung cancer and given a very short life expectancy. He
took part in an early phase chemotherapy clinical trial followed by radiotherapy which had positive effects. This led him
to believe that his experiences could help other patients and researchers and clinicians and for many years he has been
involved in numerous organisations, groups and committees. Some of his consumer/patient involvements include the NCRI
CTRad, Screening, Prevention and Early Diagnosis Advisory Group ( SPED ), Consumer Forum. CRUKCTU ( Glasgow ),
ECMC, PHE Lung Site Specific CRG, and involvement with NICE as a “ patient expert “ at Technology Appraisals. He is
very much involved in cancer research and is co applicant, collaborator, advisor on several clinical trials and sits on TMGs
and TSCs. Tom was also a member of CRUK’s Early Diagnosis Funding Application Revue Committee and is a member
and trustee of the charity Independent Cancer Patients’ Voice.
Professor Daniel Hochhauser
Kathleen Ferrier Chair of Medical Oncology and Consultant Medical Oncologist at UCL
Cancer Institute/UCLH Trust
Professor Hochhauser qualified in medicine from Cambridge and the Royal Free Hospital Medical School in 1983.
Following postgraduate medical training in London and Oxford he was appointed clinical fellow in medical oncology at the
Institute of Molecular Medicine, Oxford where he completed a DPhil. He subsequently worked as a medical oncology fellow
at Memorial Sloan Kettering Cancer Center New York before appointment as a senior Lecturer and consultant in 1996.
Professor Hochhausers major clinical interest is in gastrointestinal medical oncology. His research is focused on
development of novel therapeutics and early phase clinical studies.
Dr Rebecca Lumsden
Head of Science Policy at the ABPI
Dr Rebecca Lumsden is Head of Science Policy at the ABPI. Particular areas of focus include enhancing the UK research
and innovation environment for preclinical and early-phase research and experimental medicine. She is involved in the
ABPI’s work on antimicrobial resistance, rare diseases and precision/stratified medicines.
Her previous work at ABPI has included a strong oncology focus including representing the ABPI at the NCRI Board and
on the ECMC’s Steering Group. She has also covered activities relating to animal research, clinical trial transparency and
the use of data in medical research. Prior to joining ABPI, Rebecca worked as a Post-Doctoral Research Associate at the
MRC Laboratory for Molecular Cell Biology, UCL. She holds degrees from the University of Cambridge and the University
of Bristol.
Professor Angus Dalgleish
Professor of Oncology, George’s University of London
Professor Angus Dalgleish studied medicine at University College London where he obtained an MBBS and a BSc in
Anatomy. He is a Fellow of The Royal College of Physicians of the UK and Australia, Royal College of Pathologists and The
Academy of Medical Scientists. After graduating and house jobs in London and Poole he spent a year in the flying doctor
service in Queensland. He also trained in Internal Medicine and Oncology in Brisbane and Sydney.
Following an interest in how viruses caused cancer, he commenced an MD with Professor Robin Weiss, FRS at the Institute
of Cancer Research and Royal Marsden Hospital. Following five years as a clinical scientist at the MRC’s clinical research
centre in Northwick Park, he was appointed to the Foundation Chair in Oncology at St. George’s University of London in
1991. There his main interest has been the immunology of cancer and the development of immunotherapies to treat, in
particular, melanoma.
Professor Dalgleish, was adopted as the UKIP candidate for Sutton & Cheam and stood against incumbent MP Paul
Burstow in 2015. He also heads up “Scientists for Britain” who are a group of UK scientists and individuals who are
concerned that pro-EU campaigners are misusing science for political gain.
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
BREAST SESSION
Professor Paul Ellis, Chair
Professor of Cancer Medicine, Guy’s Hospital & Kings College London
Paul Ellis is Professor of Cancer Medicine at King’s College London and Consultant Medical Oncologist at Guy’s & St
Thomas’ Hospital with responsibility for the management of breast cancer. He studied medicine at Otago University in New
Zealand before completing his fellowship in Medical Oncology and postgraduate research degree at the Royal Marsden
Hospital in London. He took up his present post in 1997 and has held a number of senior management roles since then
including Head of Medical Oncology at Guy’s & St Thomas’, Medical Director for the South East London Cancer Network
(SELCN) and Head of Breast Cancer Clinical Research for Guy’s & St Thomas’ and the KCL Division of Cancer Medicine.
He is the author of over 100 peer reviewed scientific papers in the breast cancer field, and has been on the Editorial
Board of a number of Oncology Journals including Journal of Clinical Oncology. His major breast cancer research interests
include novel clinical research strategies in the adjuvant and neoadjuvant setting with an emphasis on the integration of
novel therapies. He was involved in chairing the UK Dept of Health Advisory committee on the introduction of Herceptin
into UK clinical practice, and co-authouring the national guidelines on Herceptin use. Professor Ellis was the principal
investigator and co-chair of the trial management group for the UK National Adjuvant Chemotherapy (TACT) Trial and has
been involved on the Steering Committees of numerous other clinical trials of novel anti-cancer therapies including recently
being Co-PI on the MARIANNE and KAMILLA trials. He continues to take an active leadership role within the UK and
European Clinical Trials community. Over the last 5 years he has been actively involved in the development and growth of
the Sarah Cannon Research Centre in London. He has taken a leadership role in the breast programme and links closely
with Sarah Cannon in Nashville and the other centres in the US. Dr Nicholas Turner (Day One)
Academic of Cancer Medicine, Guy’s Hospital & Kings College London
“What’s new in ER positive breast cancer - novel therapies and how do they fit
into UK practice”
Dr Nicholas Turner is an Academic Consultant Medical Oncologist who specialises in the treatment of breast cancer. He
is a team leader at the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research, London. Dr Turner
read Natural Sciences at Cambridge University before qualifying in 1997 from the University of Oxford Medical School.
After completing general medical training in London, he trained in Medical Oncology at Royal Free and University College
Hospitals and completed a PhD at The Institute of Cancer Research (ICR) in 2006. He joined the Breast Unit of The Royal
Marsden and the ICR as a Senior Lecturer and Honorary Consultant in Medical Oncology in 2008. He is a Cancer
Research UK Clinician Scientist fellow and devotes the majority of his time to academic research, both in the laboratory
investigating novel therapies for the treatment of breast cancer and in clinical trial research. Dr Nicholas Turner is Chief
Investigator of a number of national and international trials of personalised therapy in Breast Cancer. He is Deputy Editor of
the journal Breast Cancer Research, Breast Theme lead for the Royal Marsden NIHR Biomedical Research Centre, and on
the organizing committees of many international Conferences on Breast Cancer.
Professor Murray Brunt (Day One)
Consultant & Honorary Professor Clinical Oncology, Cancer Centre, Royal Stoke
University Hospital & Keele University
Hot and current breast radiotherapy topic “Nodal radiotherapy and
hypofractionation – including ESTRO breast radiotherapy consensus guidelines”
Murray qualified from Westminster Medical School and was appointed Consultant Clinical Oncologist at the Royal Stoke
University Hospital in 1991. He is Chief Investigator of the FAST-Forward trial and has a strong record of breast cancer
trial recruitment over the last 25 years in a large portfolio of studies. He is currently the Cancer Research Lead (CRL) for the
West Midlands NIHR-CRN and the Royal College of Radiologists lead for the breast cancer electronic forum.
Dr Michelle Kohn (Day One & Day Two)
Specialist in Supportive Cancer Care and in late 2009, she joined LOC to set up a
cancer ‘survivorship’ service, launched in early 2010 as the Living Well Programme
‘Living well for a good survival’
Dr Kohn qualified in medicine at University College and Middlesex School of Medicine, London (1990), with a distinction
in pharmacology and therapeutics and was awarded the ICI pharmacology prize. After completing further medical
training, she went on to work in the development of clinical trials. She resumed her interest in oncology and supportive
cancer care whilst working at Mount Vernon Cancer Centre (1996) and was subsequently appointed Medical Advisor to
Macmillan Cancer Support to develop their integrative oncology services and guide their supportive care activity (19982005). She was then appointed Advisor to Breakthrough Breast Cancer (2006-2007) to guide their research programme
in integrative oncology. Dr Kohn has worked with many organisations in the UK and USA to develop clinical practice,
information and research in integrative oncology and supportive cancer care, including the NCI in the USA and NCRI
in the UK. She has lectured and published widely on the subject, nationally and internationally. In late 2009, Dr Kohn
joined LOC (now, Leaders in Oncology Care) to set up a cancer ‘survivorship’ service, which was launched in early 2010
as the Living Well Programme. Dr Kohn is the Director of this innovative Programme, which has evolved, in consultation
with patients and health care professionals, to embrace total care needs beyond medical treatment, offering physical,
psychological, practical and spiritual support for patients and family members, from diagnosis through treatment and
beyond. The successful programme continues to be led and facilitated by Dr Kohn, with a growing team of professional
collaborators, who are helping develop Living Well into an integral and highly valued part of patient care. In 2012, Dr
Kohn was elected to Fellowship of the Royal College of Physicians for her work in cancer survivorship and supportive
cancer care. She has since been invited to present the Living Well Programme to audiences nationally and internationally,
as an exemplary model of cancer survivorship care.
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
BREAST SESSION
Dr Duncan Wheatley (Day Two)
Medical Doctor, Director of Research in Cornwall , Clinical Lead for Cancer Research
SW Peninsula
Hot and current breast radiotherapy topic “Nodal radiotherapy and
hypofractionation – including ESTRO breast radiotherapy consensus guidelines”
Dr Duncan Wheatley is a Clinical Oncologist at the Royal Cornwall Hospital. He has a special interest in Breast and
Urological tumours. He is Director of RD and I, Clinical Lead for Cancer Research in the Peninsula and a member of
NCRI advanced disease Clinical studies Group. He sits on the TMG for the IMPORT and FAST Trials and is Chief Clinical
Cordinator for the FAST FORWARD studies. He is a very active recruiter to many clinical studies in all stages of cancer. He
hope you enjoy the Forum and feel free to interact. More the better
Professor Peter Schmid (Day Two)
Queen Mary University of London, Barts Cancer Institute
“What’s new in TNBC - is there any role for immune checkpoint inhibitor
therapy?”
Professor Peter Schmid was appointed as Chair in Cancer Medicine at Barts Cancer Institute, Queen Mary University
London, in 2013. He is Clinical Director of Breast Cancer at the St. Bartholomew Cancer Centre and Honorary Consultant
Medical Oncologist at Barts Hospital. Professor Schmid is also Lead of the Centre of Experimental Cancer Medicine
at Barts Cancer Institute and the Barts/Brighton Experimental Cancer Medicine Centre. He leads the academic breast
cancer programme and the cancer immune therapy group at Barts Cancer Institute. Professor Schmid trained in medicine
at Ludwig-Maximilians-University Munich, Technical University of Munich and University of Aberdeen. He was awarded
scholarships by the ‘Studienstiftung des deutschen Volkes’, the ‘Hanns-Seidel-Foundation’, and the ‘Deutscher Akademischer
Austauschdienst’. Professor Schmid completed a MD on mitochondrial creatine kinase at the Technical University Munich.
He subsequently trained at the University Hospital Charité in Berlin in internal medicine, haematology and oncology, where
he became head of breast cancer research and the phase I programme. He completed his PhD at the Charité University
in Berlin in 2005 and was awarded the “habilitation and venia legendi” and an external readership by the Charité
University in 2006. From 2005-2010, Prof. Schmid was a Senior Clinical Lecturer and Director of the Hammersmith Early
Clinical Trials Unit at Imperial College London. In 2010, he was appointed as Foundation Chair in Cancer Medicine
at the University of Sussex, and he was Director of the Clinical Investigation and Research Unit at Brighton and Sussex
University Hospitals until his move to Barts. Professor Schmid’s specialist cancer interests are breast cancer, cancer immune
therapy and early drug development. His research interests lie in stratified cancer medicine utilising novel biomarkers and
innovative, biomarker-driven clinical trial strategies to develop new treatment strategies. Professor Schmid has successfully
led more than 20 national/international academic clinical studies, ranging from phase I to III, and several translational
research programmes. He leads a collaborative group to establish circulating tumour DNA as a biomarker and is principal
investigator of 2 ongoing, prospective international biomarker studies on predictive epigenetics from circulating tumour
DNA. Professor Schmid is a member of several national and international cancer organizations and research groups and
has been involved in international consensus meetings on the management of breast cancer. Professor Schmid is a member
of ESMO breast cancer Faculty, the UK NCRN breast cancer study group and of the breast cancer and translational
research steering groups of the German cooperative group of medical oncology. He has authored or –co-authored 145
publications and has published a book on the management of bone metastases (3rd edition).
PRACTICAL DELIVERY OF PERSONALISED MEDICINE
Professor Manuel Salto-Tellez, Chair
Clinical Professor, Queens University Belfast, Centre for Cancer Research and Cell
Biology
“Next Generation sequencing - clinical research, clinical trials and routine
diagnostics”
Professor Manuel Salto-Tellez (MD-LMS, FRCPath, FRCPI) is the Chair of Molecular Pathology at Queen’s University Belfast,
Clinical Consultant Pathologist at the Belfast Health and Social Care Trust and Deputy Director of the Centre for Cancer
Research and Cell Biology. By April 2015, Prof Salto-Tellez was author or co-author of more than 200 internationally
peer-reviewed articles in translational science, molecular pathology and diagnostics, including work published in NEJM,
Nature Medicine, Gastroenterology, FASEB, EMBO, Cancer Research and Clinical Cancer Research, among others.
He has published a similar number of abstracts in international conferences, and is editor or contributor to some of the
key textbooks of pathology and oncology. Professor Salto-Tellez studied Medicine in Spain (Oviedo), Germany (Aachen)
and The Netherlands (Leiden). He specialized in Histopathology in the UK (Edinburgh and London) and in Molecular
Pathology in USA (Philadelphia). For more than 10 years he worked at the National University of Singapore and its
National University Hospital, where he was associate professor, senior consultant, director of the Diagnostic Molecular
Oncology Centre, Vice-dean for Research and senior scientist at the Cancer Research Institute. Prof Salto-Tellez serves in
the following committees: Interspecialty Committee on Molecular Pathology in the Royal College of Pathologists of Great
Britain and Ireland; Colorectal Group of the UK National Cancer Research Institute; Molecular Pathology Committee of
the Association of Clinical Pathology; Advisory Committee on Pathology Education of Targos Molecular Pathology gmbh;
Executive Group of the Confederation of Cancer Biobanks, National Cancer Research Institute and Cancer Research UK
Biomarker Expert Review Panel. He is in the editorial board of the following journals: Journal of Clinical Pathology, Expert
Opinion on Molecular Diagnostics, Cytopathology, Journal of Oncopathology and Pathogenesis. He holds more than £5M
in competitive grant funding. Prof Salto-Tellez leads the Northern Ireland – Molecular Pathology Laboratory (NI-MPL). This
is a hybrid laboratory that is CPA accredited to take care of the molecular diagnostics of the whole of NI (population =
1.8 million) and, at the same time, support the translational research mission of the Centre for Cancer Research and Cell
Biology.
Professor Richard Kennedy
Professor of Medical Oncology, Queens University Belfast
“Gene expression arrays and molecular diagnostics”
Richard Kennedy Is the McClay Professor in Medical Oncology at the Centre for Cancer Research and Cell Biology,
Queen’s University of Belfast. He graduated in medicine from Queen’s University Belfast in 1995. As a post-graduate
he trained as a medical oncologist and received a PhD in Molecular Biology in 2004. From 2004-2007 he worked as
an instructor in oncology at Harvard Medical School, USA, where he identified novel biomarkers and drug targets for
cancer treatment. This work was published in several high impact journals and the associated patent was in-licensed by a
Boston-based start up company (DNAR) in 2007. In August 2007 he joined Almac Diagnostics as the director of a CLIA
compliant diagnostics laboratory and has been involved in the biomarker design for several international clinical trials.
In 2012 he joined Queen’s University and has established a research group focussed on various aspects of stratified
medicine. He also continues to manage cancer patients as a Consultant in Medical Oncology at Belfast City Hospital.
He is currently the Experimental Cancer Medicine Centre lead for Northern Ireland and sits on the CR-UK new agents
committee, MRC Biomarkers steering group, the National Cancer Clinical Trials Steering Group, the Enterprise Ireland
Technology assessment panel and the all-Ireland Breast Cancer Predict Consortium. Previously he was a member of the CRUK biomarker steering group and the Breast Cancer Campaign scientific advisory board
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
PRACTICAL DELIVERY OF PERSONALISED MEDICINE
Dr Rachel Butler
Consultant Clinical Scientist, Cardiff & Vale NHS Trust
“Baseline single-gene testing in oncology”, and a practical review to oncologists
of RAS, BRAF, EGFR, ALK and other tests.
Rachel is the Head of the All Wales Genetic diagnostic laboratory. The accredited laboratory provides genetic diagnostic
analyses for over 50 genetic disorders (including both common and rare genetic conditions) and increasingly stratified
medicine targets, handling over 20,000 samples each year. Rachel is actively developing the lab’s portfolio of molecular
assays for solid tumours in response to clinical demand, and working with clinical teams to determine the validity and utility
of these markers. The lab is one of the CRUK’s Stratified Medicine Technology Hubs, and Rachel is a grant holder for a
number of stratified medicine clinical trials. Rachel is a Fellow of the Royal College of Pathologists in Molecular Genetics,
and the Lead Examiner for Molecular Pathology.
Professor Gareth Thomas
Professor of Experimental Pathology, University of Southampton
“Practical Cancer Immunology testing”
Gareth Thomas was appointed to the Chair of Experimental Pathology at the University of Southampton in 2009. He
trained in Oral and Maxillofacial Pathology at University College Hospital, London, gaining his FDSRCS in 1994,
MRCPath in 2004 and FRCPath in 2008. He undertook his PhD as an MRC Clinical Fellow at University College London
and the Richard Dimblebey Department of Cancer Research, studying the functional role of integrins in keratinocyte biology
(1996-1999). In 2004 he was awarded a Clinician Scientist Fellowship from the Heath Foundation/Royal College of
Pathologists to develop novel tumour therapies in squamous cell carcinoma. He was appointed Chair of Oral Pathology
and Consultant in Oral and Maxillofacial Pathology at Barts and the London in 2007. He leads the Experimental
Pathology Research Group in Southampton, investigating the role of the microenvironment in promoting tumour progression.
The work has a strong translational component, identifying potential prognostic biomarkers, therapeutic targets and
molecular classifiers in cancer tissues, including the characterisation of cancer-associated fibroblasts and intratumoral
immune cells, and development of immunotherapy clinical trials in squamous carcinoma of the head and neck..
DELIVERING CARE TO THE UK NHS CANCER PATIENT
Dr Shelley Dolan, Chair
Chief Nurse / Director of Infection Prevention & Control Nursing, Risk and Quality The
Royal Marsden Hospital
Shelley Dolan has worked in critical care and in cancer since 1990. In 2000 Shelley was the first Nurse Consultant
in Cancer: Critical Care to be appointed in the UK. In June 2007 Shelley was appointed as Chief Nurse of The Royal
Marsden NHS Foundation Trust and in 2015 as Executive Director of the Cancer Vanguard in West London with
colleagues from UCLH and The Christie. Shelley has chaired a London Research Ethics committee for the last 10 years and
is the co-chair of the AUKUH Clinical Academic Careers Group.
Dr Natalie Pattison
Senior Clinical Nursing Research Fellow/Trust Lead for User Involvement in Research,
The Royal Marsden NHS FT
“Precision nursing, a way to ensure personalised cancer care?
Dr Natalie Pattison is Senior Clinical Nursing Research Fellow at the Royal Marsden NHS Foundation Trust. She has
worked as a nurse in cancer and critical care since 1998 and has also worked in critical care outreach. Her clinical
experience is in critical care and cancer care, and she still works in clinical practice, running critical care follow-up clinics.
She has a doctorate in end-of-life care in critical care and has undertaken and published research studies exploring the
impact of outreach, and the characteristics of outreach patients. She is currently exploring end-of-life transitions in acute
illness and the role of critical care outreach in these. She has varied research experience, leading and collaborating
in international and national funded studies in cancer and critical care. She is also the trust lead for Patient and Public
Involvement in research. She is on the oversight and organising committees of the UK Critical Care Research Group and
is Secretary of the National Outreach Forum. Natalie is also a member of the NIHR National Specialty Group for Critical
Care, on the European Federation of Critical Care Nursing Associations scientific advisory board, and is an Associate
Editor of the European Journal of Cancer Care. She has over 45 publications and her studies and research interests
include: end-of-life care in critically ill cancer patients; end-of-life care in critical care outreach, supportive care in cancer,
user involvement in research, critical care outreach; cancer critical care, and critical care follow-up
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
DELIVERING CARE TO THE UK NHS CANCER PATIENT
Professor Mary Wells
Professor Nursing, Midwifery, AHP research, Stirling University Nursing contribution to
improving outcomes after treatment
“Nursing contribution to improving experiences and outcomes after treatment”
Mary is Professor of Cancer Nursing Research and Practice at the NMAHP Research Unit, University of Stirling. As a
cancer nurse with a clinical academic background in health services research within oncology, her research focusses on
the supportive care of people with cancer and in particular the needs, experiences and outcomes of cancer survivors.
Mary works closely with a number of cancer charities with a major interest in improving experiences, outcomes and cancer
care practice. She was a member of the Executive Board of the European Oncology Nursing Society (EONS) www.
cancernurse.eu from 2009 – 2015 (and Secretary from 2011-2015) and she is currently co-chair of the EONS Research
Working Group. Since 2009 she has been a Specialist Advisor to the leading cancer charity Macmillan Cancer Support
and the Consequences of Cancer Treatment Collaborative and she is on the Clinical Advisory Board of the Throat Cancer
Foundation. Mary was appointed as a Trustee of Health Talk (previously DiPeX) this year. She has been a member of the
NCRI Psychosocial Oncology and Survivorship Clinical Studies Group (CSG) since 2013 and has led the Interventions
sub-group since 2015.
Dr Carole Farrell
Nurse & AHP Research Fellow, The Christie NHS FT
“The impact of chemotherapy on patients over 65 years”
Expert nursing and influencing care for the frail elderly receiving chemotherapy Carole Farrell is a Nurse Research Fellow at
The Christie NHS Trust in Manchester. She leads academic nursing research studies that focus on exploring and improving
patients’ and carers’ experiences of cancer and treatment, enhancing nurses’ roles and improving service delivery. In
addition she works closely with clinical colleagues to improve research capability and capacity, and develop a portfolio
of projects that will have a direct impact on patient care and clinical services. Carole has extensive clinical experience as
an oncology nurse for almost 30 years. Previous roles include a clinical nurse specialist and advanced nurse practitioner,
where she set up nurse-led clinics and managed a large caseload of patients within them to improve continuity of care for
patients. Carole is also an Honorary Lecturer at The University of Manchester and Consultant Editor of Cancer Nursing
Practice. Her book on “Advanced nursing practice and nurse-led clinics in oncology” was published in September 2015.
Mrs Netty Kinsella
Uro-oncology nurse consultant, The Royal Marsden
“Improving patient experience through stratification of the prostate cancer
pathway”
Ms Netty Kinsella is a Uro-Oncology Nurse Consultant at The Royal Marsden Hospital where she is responsible for a team
of 10 urology nurse specialists, advanced nurse practitioners and surgical care practitioners. Her current projects include
quality service improvement initiatives and the implimentation of a multi-professional survivorship clinic experience into the
prostate cancer pathway. She completed a Diploma of Higher Education Nursing Studies at the University of Portsmouth,
an MSc in developing cancer nursing practice at the University of London and is currently writing her PhD thesis on active
surveillance in prostate cancer at King’s College, London. Previously Ms Kinsella was an Advanced Nurse Practitioner
at Guy’s and St Thomas’ NHS Foundation Trust where she played a key role in prostate cancer diagnostics as well as
managing the Active Surveillance patient caseload and monitoring erectile dysfunction and PSA in post-treatment follow up.
She was also Lead Nurse for the Prostate Cancer Charity between 2000 and 2003.
LOWER GI
Professor Richard Wilson, Chair
Clinical Professor, school of medicine, dentistry and biomedical sciences, Queen
University Belfast
I qualified in medicine in Queen’s University Belfast, then worked in N. Ireland and Scotland as a junior doctor, including 3
years basic science research in colorectal cancer. Subsequently, I trained in clinical oncology achieving UK accreditation,
and then undertook a Visiting Fellowship in the National Cancer Institute in the USA, where I trained in medical oncology,
early phase clinical trials, clinical pharmacology and drug development. In 2001, I was jointly appointed as a Consultant
and Senior Lecturer in Medical Oncology between the Belfast Health and Social Care Trust and Queen’s University Belfast.
I set up the first phase I/II cancer trials programme in Ireland, and also the N. Ireland Cancer Trials Network, for which I
am Clinical Director. I work as a gastro-intestinal medical oncologist (mainly colorectal but also small bowel cancer and
peritoneal malignancies) and conduct biological and translational research in these diseases. I am now Professor in Cancer
Medicine in the Centre for Cancer Research and Cell Biology at QUB. I currently chair the UK National Cancer Research
Institute Colorectal Cancer Clinical Studies Group. I am Chief Investigator on a variety of local, national and international
phase I, II and III cancer clinical trials. I chair the International Rare Cancer Initiative Small Bowel Adenocarcinoma
Working Group, and am CI of Global BALLAD, the first ever adjuvant randomised controlled trial in this disease. I am also
CI of the adjuvant colorectal cancer trial in Add-Aspirin, an international phase III trial programme in colorectal, breast,
gastro-oesophageal and prostate cancer. My major interest is in personalised medicine, and I am co-CI on the FOCUS4
trial in metastatic colorectal cancer which has been funded by Cancer Research UK and the Medical Research Council as
the flagship UK trial in precision medicine in oncology. Finally, I am a football pundit and confidently predict that N. Ireland
will easily win the ongoing European Championships.
Professor Sir John Burn
Professor of Clinical Genetics, Newcastle University, Chair Genetics Specialty Group,
National Institute of Health Research, Director of the Collaborative Group of Genetics in
Healthcare (NIHR and Dept of Health)
”Aspirin Zsar”
Consultant Clinical Geneticist in the Northern Genetics Service since 1984, Professor of Clinical Genetics, Newcastle
University, over 400 publications. Knighted for services to Medicine and Healthcare 2010. Chief Investigator CaPP, the
international Cancer Prevention Programme, which has shown aspirin can prevent hereditary colorectal cancer. Conceived
and helped create the Millennium Landmark Centre for Life. Former chair British Society for Genetic Medicine, and of
European Society of Human Genetics. Senior Investigator, National Institute Health Research. Director Collaborative Group
for Genetics in Healthcare and chair of Department of Health Rare Disorders Databases and Registries Advisory Group.
Non-executive director NHS England.
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
LOWER GI
Dr Richard Adams
Clinical Reader of Oncology & Palliative Medicine, Cardiff University School of
Medicine
“Controversies around adjuvant therapy following chemoradiotherapy for rectal
cancer”
Richard Adams is a reader and Director of the Wales Cancer Trials Unit and Wales Cancer Bank. His clinical practice
and research is focused on lower gastrointestinal cancers. He is chair of the NCRI anorectal subgroup and is active in
national and international research organisations including IRCI the International Rare Cancer Initiative (for anal cancer)
and ARCAD. He chairs the biomarker development group for FOCUS4 is Chief investigator for FOCUS4 D and leads
on the radiotherapy quality assurance for the UK ARISTOTLE, COPERNICUS and TREC trials. He oversees collaborative
translational research in numerous phase II/ III colorectal cancer trials. He was a founder member of and now chairs the
South Wales Cancer Care link with Sierra Leone.
Professor Andrew G Renehan PHD FRCS
Professor of Cancer Studies and Surgery, University of Manchester and Honorary
Consultant, Manchester Colorectal and Peritoneal Oncology Centre, The Christie NHS
Foundation Trust.
“Surgery for peritoneal malignancies“
Andrew Renehan is Professor of Cancer Studies and Surgery at the Institute of Cancer Sciences, The University of
Manchester. His major academic profile is lead for the Manchester Cancer Research Centre (MCRC) Obesity and Cancer
Research Group; lead for the Farr Institute@HeRC Diabesity and Outcome Theme; chair of the International Diabetes
and Cancer Research Consortium; and chair of the European Association for the Study of Diabetes (EASD) Cancer
Study Group. He is a member of International Agency for Cancer Research writing group for the Handbook on ‘Cancer
Prevention: Weight Control’. He is honorary consultant colorectal surgeon and core member of the Peritoneal Tumour
Service at The Christie NHS Foundation Trust, Manchester. He has written several papers on the topic of peritoneal
malignancies and pioneered the field of conservative management of early appendiceal tumours. He has authored or coauthored on over 160 publications; 13 book chapters, and edited two books.
Dr Mark Harrison
Consultant Oncologist, Mount Vernon Hospital
“Stereotactic body radiotherapy in colorectal cancer”
Dr Harrison is a Consultant Oncologist at the Mount Vernon Hospital, Northwood, London. He trained at the Royal Free
Hospital in London, followed by Cambridge, Hammersmith, St Mary’s, Middlesex and Great Ormond Street Hospitals.
He holds a PhD in Cell Biology, which he received for his research at the Clare Hall Laboratories in London. His research
focus includes Stereotactic Body Radiotherapy for GI malignancies, chemoradiation of oesophageal and ano-rectal cancer,
and integration of new agents into upper GI tract cancer treatment schedules. He is currently the regional advisor of The
Royal College of Radiologists and a member of a number of National Cancer Research Network subgroups. He is also
the clinical lead of the NICE oesophago-gastric guidelines group, a lecturer at the PELICAN centre and a module leader
in Cell Biology at the Institute of Cancer Research. Dr Harrison is author and co-author of over 70 articles, abstracts and
presentations over the past 5 years. These include reviews and original reports on preoperative therapy of rectal cancer,
radical and palliative management of oesophago-gastric cancer and novel imaging and radiotherapy planning techniques
in anal cancer
Dr Vicky Coyle
Senior Lecturer, Queens University Belfast
“Exercise in the management of colorectal cancer“
Vicky Coyle is a senior lecturer in Queens University Belfast and a consultant medical oncologist in the Belfast Trust. Her
clinical practice and research interests focus on translational research and clinical trials in colorectal cancer along with
supportive care trials in oncology
LUNG & MELANOMA
Dr Marianne Nicolson, Chair
Consultant Medical Oncologist and Honorary Senior Lecturer to NHS Grampian
Dr Marianne Nicolson is a Consultant Medical Oncologist and Honorary Senior Lecturer at the Aberdeen Royal Infirmary.
She has held her current post since 1994 and specialises in various tumour types, mainly lung cancer. She is chair of the
National Cancer Research Institute (NCRI) lung cancer clinical study group and a former member of the Scottish Medicines
Consortium. She is a member of the SIGN guidelines development group for lung cancer and melanoma. Dr Nicolson is
active in clinical research for lung cancer.
Professor Peter Goldstraw
Emeritus Professor of Thoracic Surgery, National Heart and Lung Institute, Imperial
College, Honorary Consultant in Thoracic Surgery, Royal Brompton Hospital, London.
“IASLC Staging Surgical Data”
Peter Goldstraw graduated from the University of Birmingham in the UK in 1968. He was appointed Consultant Thoracic
surgeon at the Brompton Hospital in 1979 and has held appointments at the Whittington Hospital, University College
Hospital, the Middlesex Hospital, Benenden Hospital and with the Royal Navy and the Royal Air Force. He is now
Honorary Consultant in Thoracic Surgery to the Royal Brompton Hospital and Emeritus Professor of Thoracic Surgery at
the National Heart and Lung Institute, Imperial College, London, UK. He has given over 400 lectures at International
and National conferences. He received the Price Thomas Gold Medal from the Royal College of Surgeons of England
in 2004, awarded triennially in recognition of meritorious contributions in surgery. He has been honoured with a Lifetime
Achievement Award by the British Thoracic Oncology Group in 2006 and the Society for Cardiothoracic Surgery in Great
Britain and Ireland in 2010. He received honorary membership of the ESTS in 2007 and the Merit Award by the IASLC in
2007. He has published over 300 peer-reviewed articles and 58 chapters in specialist textbooks. He has been a member
of the IASLC since 1985 and has been involved in every WCLC since the 4th. He chaired the IASLC Staging Project from
its inception in 1998 until the publication of the 7th edition of TNM in 2009 and was executive editor for the first edition
of the Staging Handbook and Manual in Thoracic Oncology published by the IASLC/UICC/AJCC. He continues as a
member of the IASLC Staging and Prognostic Factors Committee and lead the writing committee for the Group Staging
aspect of the 8th edition of TNM for Lung Cancer. He was president of the International Association for the Study of Lung
Cancer from 2011 - 2013 and a board member from 2009 - 2015.
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
LUNG & MELANOMA
Professor Keith Kerr
Consultant Pathologist, Aberdeen Royal Infirmary
“The Pathology of Patient Pathology”
Keith Kerr has been a Consultant Pathologist in Aberdeen since 1989, following under and post-graduate education in
Edinburgh. He was awarded an Honorary Chair in Pulmonary Pathology at the University of Aberdeen in 2006. Research
interests include lung pre-neoplasia and carcinogenesis, lung tumour diagnosis and classification, and therapy biomarkers.
He is a member of numerous national and international lung cancer clinical advisory and research groups - BTOG steering
group, Pulmonary Pathology Society Council, ETOP Foundation Council, ESMO Educational Faculty (thoracic tumours), and
is an elected Board member of the IASLC. He is former Pathology Chair - EORTC lung group, and is Pathology lead for
ETOP Lungscape project. He is a member of the IASLC Pathology committee, the WHO panel for lung cancer classification
and the International Mesothelioma panel. He works on UK, European and North American committees for developing
guidelines for management of, and molecular pathology testing in, lung cancer.
Dr Paul Nathan
Consultant Medical Oncologist, Mount Vernon hospital
“Side-effect management of immunotherapy”
Dr. Nathan is consultant medical oncologist at Mount Vernon Cancer Centre, Northwood, UK. His specialist interests are
the treatment of malignant melanoma and renal cell carcinoma. His clinical training was through Cambridge and London
having had an earlier scientific career in the pharmaceutical industry. He chairs the NCRI Renal Carcinoma Clinical Studies
Group, chaired the development of UK guidelines for the management of uveal melanoma and is co-author of the UK
cutaneous melanoma guidelines. He leads a number of academic studies on the national portfolio. He is chief investigator
of SELPAC, a uveal melanoma study, is co-CI of PERM which is investigating the abscopal effect induced by radiotherapy
in melanoma patients receiving pembrolizumab, and leads the national Merkel cell study UKMCC-1. He is UK chief
investigator and steering committee member for a number of pharma sponsored melanoma studies. He is a trustee of the
charity Melanoma Focus and is contributing to the initiative to develop a UK national melanoma database.
PROSTATE
Professor Amit Bahl, Chair
Consultant Clinical Oncologist and Clinical Director, Bristol Haematology and Oncology
Centre
Amit Bahl is Consultant Clinical Oncologist and Clinical Director at Bristol Haematology & Oncology Centre with a special
interest in breast and urological cancers. He is the research lead for Bristol Haematology and Oncology Centre. He has
led and developed the prostate brachytherapy service at Bristol. He has been an expert adviser to NICE for the technology
appraisal on new drugs and an external service reviewer at oncology departments elsewhere in the country. Prior to his
current roles, Dr Bahl became Member of the Royal College of Physicians (UK) and trained in Clinical Oncology, achieving
the Fellowship of the Royal College of Radiologists qualification. He has been awarded the fellowship of the Royal College
of Physicians. He is a current member of the National Cancer Research Institute Clinical Studies Groups for prostate and
bladder cancer, college tutor of the Royal College of Radiologists and has supervised several MD theses in breast and
prostate cancer research. He has previously been in the NCRI Renal clinical studies group. He is an Executive Committee
member of the British Uro-oncology group. Dr Bahl is actively involved in research into breast, prostate and bladder
cancers, participates in clinical trials locally and nationally and regularly publishes articles in these research areas and has
several presentations at national and international meetings. In 2012, Dr Bahl was awarded the Cochrane Shanks Jalil
Professorship by the Royal College of Radiologists, London.
Professor Noel Clarke (Day One)
The Christie NHS foundation Trust
“Lessons from National Prostate Cancer Audit”
Noel Clarke has been a consultant urologist at Salford Royal Hospital and The Christie, Manchester, since 1993 and was
made honorary professor of urological oncology by Manchester University in 1997. His specialist expertise is in prostate,
bladder, renal and testis cancer and complex pelvic and retroperitoneal malignancy. Professor Clarke is a former director
of urology at both Salford and The Christie, chair of the Manchester and Cheshire clinical study group (CSG) and National
Cancer Research Institute prostate CSG. He is currently director of Manchester University’s Genitourinary Cancer Research
Group, a member of the Department of Health and National Cancer Research Network prostate cancer advisory boards,
chair of the European Organisation for Research and Treatment of Cancer prostate disease group and author of over 150
publications, including eight book chapters on urological cancer. Professor Clarke has planned and managed multiple trials
in the UK and Europe and given various national and international guest lectures on urological cancer.
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
PROSTATE
Professor Johann De Bono (Day One & Day Two)
Professor in experimental Cancer Medicine, The Institute of Cancer Research, London
“Advances in managing metastatic prostate cancer with particular emphasis on
genomics”
Professor Johann de Bono is a Professor in Experimental Cancer Medicine at The Institute of Cancer Research and Royal
Marsden. He is the Director of The Drug Development Unit, overseeing the conduct of Phase I trials, with a particular
interest in innovative trial designs, circulating biomarkers and prostate cancer. He also leads the Prostate Cancer Targeted
Therapy Clinical Trials Team and the Cancer Biomarkers laboratory team. He graduated from the University of Glasgow
medical school in 1989, graduating as a Member of the Royal College of Physicians (MRCP) in 1992. He was awarded
a four-year Cancer Research Campaign Clinical Fellowship, which allowed him to pursue a PhD between 1993 and
1997. He trained in medical oncology, and was awarded an MSc (Cancer Sciences) from Glasgow University. The Royal
College of Physicians and Surgeons of Glasgow then awarded him a travelling scholarship that allowed him to pursue
further research on the challenges of clinical trial design at the SWOG statistical headquarters at the Fred Hutchinson
Cancer Centre in Seattle, USA in 1999. Between 2000 and 2003 he then pursued further research developing novel
anti-cancer drugs at the Institute for Drug Development within the University of Texas Health Science Centre at San Antonio.
In 2003, he was elected a Fellow of the Royal College of Physicians, and in 2009, he was elected as a Member of the
Malta Order of Merit. Professor de Bono received the prestigious ESMO Award in 2012 and was part of the ICR/RMH
team awarded the AACR Team Science Award. He also received an award from the Royal Society of Chemistry for his
team’s work in developing abiraterone. Professor de Bono has been involved in the development of many novel agents,
many of which are now approved drugs, functioning as chief investigator on Phase I trials such as abiraterone, olaparib
and afatinib. He has served as chief investigator of multiple drugs that have changed the standard of care for prostate
cancer patients including abiraterone, cabazitaxel and enzalutamide and has published more than 300 manuscripts
including multiple publications in the New England Journal of Medicine and The Lancet. He has led on the study of
circulating tumour cells, whole blood expression profiling and plasma DNA in metastatic prostate cancer patients and
pioneered the concept of patient molecular stratification in early clinical trials in the Pharmacological Audit Trail.
Dr Nicholas Van As (Day Two)
Medical Director of The Royal Marsden and Consultant Clinical Oncologist in Urology
“Oligometastatic Disease”
Dr Nicholas van As was appointed Medical Director of The Royal Marsden in January 2016. He has been a Consultant
Clinical Oncologist in the Urology Unit in the hospital for eight years and is Clinical Lead for stereotactic body radiotherapy
(SBRT) and CyberKnife. Dr van As is also Co-Chair of the UK SBRT Consortium and the national clinical lead for NHS
England’s Commissioning through Evaluation Programme for SBRT. His main research interests are in stereotactic and
image-guided radiotherapy, risk prediction in early prostate cancer, and functional MRI and he has published numerous
papers on these subjects and delivered presentations at international meetings. He is the Chief Investigator for the PACE
trial – an international, randomised controlled trial comparing SBRT to image-guided Radiotherapy (IGRT) and surgery for
treating prostate cancer.
RADIOTHERAPY
Professor David Sebag-Montefiore, Chair
Professor of Clinical Oncology University of Leeds
“Innovative Radiotherapy Clinical Trials Design”
David Sebag-Montefiore qualified at St Bartholomew’s Hospital, London and trained in clinical oncology at Middlesex,
Mount Vernon and St Bartholomew’s Hospitals. He was subsequently appointed Consultant in Clinical Oncology in
Leeds. In 2012, he took up his post as the Audrey and Stanley Burton Professor of Clinical Oncology at the University
of Leeds. His research interests focus on improving outcomes for patients with gastrointestinal cancer using radiotherapy.
He is a member of the National Cancer Research Institute Colorectal Study Anal and Rectal Group and the Clinical and
Translational Radiotherapy Group (CTRad) and chair of the anal and rectal cancer subgroups until 2012. He is Chair
of Cancer Research UK’s Clinical Trials Awards and Advisory Committee. Rectal cancer research interests include the
development of high quality multi-disciplinary management of rectal cancer through the MERCURY study group with a focus
on the role of pelvic MRI staging and national training programmes such as the low rectal cancer educational courses
(LOREC). He is Chief Investigator of the Medical Research Council CR07 rectal trial with recent publications in the Lancet
and Journal of Clinical Oncology and the on-going phase III ARISTOTOLE trial testing the role of novel chemoradiation
in MRI defined locally advanced rectal cancer. He also co-led the largest international trial in anal cancer (ACT2),is a
member of the anal cancer International Rare Cancer Initiative (IRCI) and leads the PLATO anal cancer trials consortium.
Dr Kevin Franks
Consultant Clinical Oncologist and Honorary Associate Professor, Leeds Cancer Centre
and University of Leeds
“Stereotactic Ablative Radiotherapy (SABR) – Current & future indications”
Kevin Franks (MBChB, MRCP, FRCR) is Consultant Clinical Oncologist and Honorary Clinical Associate Professor at the
Leeds Cancer Centre, Leeds Teaching Hospitals, and the University of Leeds.. Dr Franks trained as clinical oncologist in
Leeds and completed a two-year clinical research fellow in lung technical radiotherapy at Princess Margaret Hospital
under the supervision of Professor Andrea Bezjak and David Jaffray (2005-2007). He was appointed as consultant in
Leeds in 2009 and as the clinical Lead for Lung Stereotactic Ablative Radiotherapy (SABR) he has established a large lung
SABR program treating more than 700 patients since 2009. In the UK, Dr Franks is a founding member of the UK SABR
Consortium and is a member of the National Clinical Research Institute Clinical and Translational Radiotherapy Research
Group (work stream 4). He was the co-chair of the National Cancer Action Team (NCAT) Image-guided Radiotherapy
working group, which produced national guidelines on IGRT use in 2012 and is a member of the British Thoracic Society
working group, which has produced guidelines for the investigation and management of pulmonary nodules (published
2015). Dr Franks’ research interests are in technical radiotherapy including 4DCT, SABR, image guided radiotherapy
(IGRT), intensity + volume modulated radiotherapy (IMRT/VMAT), combination of novel agents with RT/SABR and
radiotherapy/cancer informatics. He is the principal investigator for the SABRtooth trial, a study to determine the feasibility
and acceptability of conducting a phase III randomised controlled trial comparing Stereotactic Ablative Radiotherapy
(SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered To be at Higher risk
of complications from surgical resection, which started recruitment in 2015.
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
RADIOTHERAPY
Dr Alison Tree
Consultant Clinical Oncologist Royal Marsden Hospital and Institute of Cancer Research
“MR Linear Accelerator radiotherapy – what willit offer and who should we
treat?”
Alison Tree was appointed as a consultant clinical oncologist at The Royal Marsden in 2014, specialising in radiotherapy
and chemotherapy treatment for urological malignancies. Prior to this she spent most of the previous 12 years at the Royal
Marsden, training in state of the art chemotherapy and radiotherapy techniques. Her MD thesis was on stereotactic body
radiotherapy (SBRT) for prostate and oligometastatic cancer. Her current research interests include technical radiotherapy
improvements in prostate cancer, the development of the MR Linac for urological cancers and the use of ablative
radiotherapy for oligometastatic disease
Professor Anthony Zietman
Massachesetts General Hospital and Harvard Medical School
“Proton beam therapy – the good and the bad: a US perspective”
Professor Zietman received his undergraduate training at Oxford University in the UK and then went to medical school at
the Middlesex Hospital, London University graduating in 1983. After residencies in internal medicine and clinical oncology
he moved to the Massachusetts General Hospital in Boston, USA for a fellowship in radiation biology. Since joining the
staff he has authored over 200 original articles and reviews on many aspects of GU cancer. His particular research
interests are in the specific roles of active surveillance, brachytherapy, hormone therapy, and proton beam therapy in the
treatment of prostate cancer. He also has a long-standing interest in the organ-sparing management of bladder cancer.
He is currently the Jenot and William Shipley Professor of Radiation Oncology at Harvard Medical School, Editor-in-Chief
of the International Journal of Radiation Oncology, Biology, Physics, Trustee of the American Board of Radiology, and the
former President and Chair of the American Society for Radiation Oncology (ASTRO)
UPPER GI
Dr Martin Eatock, Chair
Consultant/Honorary Senior Lecturer in Medical Oncology, Medical Director, Northern
Ireland Cancer Network
Dr Eatock qualified in medicine from the University of Edinburgh and trained in Oncology in Manchester and Glasgow.
He took up post as a Consultant and Honorary Senior Lecturer in Medical Oncology in Belfast in 2000 and is an active
member of the Upper Gastro-intestinal, Hepato-pancreatobiliary and Neuro-endocrine tumour teams. He has clinical
and research interests in gastro-intestinal cancer and drug development and is currently chief investigator for a number
of national and international clinical trials in upper GI malignancy. Dr Eatock was appointed as Medical Director to the
Northern Ireland Cancer Network in 2012 and has overseen the re-development of the Network since then with an
expansion in the network site specific groups and the introduction of Peer Review of Cancer MDTs in Northern Ireland
Mr James Gossage (Day One)
Consultant General Surgeon, Guy’s & St Thomas’ NHS Foundation Trust
“Surgery for Oesophageal cancer in the 21st Century: Current Practice and
future developments”
Case Discussions
James Gossage is a Consultant Upper Gastrointestinal Surgeon at Guy’s and St Thomas’ Hospitals NHS Foundation
Trust, specialising in cancer of the oesophagus and stomach and benign disease of the upper digestive tract. He is
currently Upper GI Surgical Lead at the trust and is the regional representative on the council for the Association of Upper
Gastrointestinal Surgeons (AUGIS). After completing his training in London, he was awarded a laparoscopic surgical
fellowship and a HCA Foundation grant to study surgical techniques in the Professorial Unit in Adelaide, Australia. He
also received a Royal College of Surgeons grant to enable him to train in trauma surgery in South Africa. His specialist
expertise is in oesophageal and gastric cancer as well as keyhole surgery for conditions such as gastro-oesophageal
reflux, achalasia, GIST tumours and hiatus hernias. He has a strong academic background and was awarded a Hunterian
Professorship from the Royal College of Surgeons for his research during his higher degree. He is currently a Senior Lecturer
at Kings College, London and an affiliated researcher with the Upper Gastrointestinal Research Unit at the Karolinska
Institute, Sweden. He has published over 40 peer-reviewed articles on his specialist area, two book chapters and a
textbook on surgery
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
UPPER GI
Dr Somnath Mukherjee (Day One & Day Two)
Clinical Oncologist, University of Oxford
PROPOSER; Debate: This house believes that the optimal neoadjuvant treatment
for operable oesopahageal adenocarcinoma is with chemo-radiotherapy.
Dr Somnath Mukherjee is a Senior Clinical Researcher and Honorary Clinical Oncologist at University of Oxford
and Churchill Hospital. His main research interests include chemoradiation for pancreatic and upper gastro-intestinal
malignancy. He was the chief investigator of the SCALOP trial, which established the practice of modern pancreatic
chemoradiotherapy in the UK. He is currently leading SCALOP2 trial, the largest pancreatic chemoradiation trial in the
UK, and is a co-investigator of other pancreatic chemoradiation studies. He is a member of several national research
committees including the NCRI upper GI Clinical Studies Group, the NCRI Pancreatic subgroup, NCRI Oesophago-gastric
subgroup and National Radiotherapy research group, CTRAD. He has participated as a member of ASCO guideline
writing committee for locally advanced pancreatic cancer, and is currently member of the ESTRO pancreatic radiotherapy
guideline committee and the NICE pancreatic guideline committee.
Dr Stephen Falk (Day One & Day Two)
Clinical Oncologist, University Hospitals, Bristol
OPPOSER; Debate: This house believes that the optimal neoadjuvant treatment
for operable oesopahageal adenocarcinoma is with chemo-radiotherapy.
Stephen qualified from Liverpool University in 1983 and spent a period in Liverpool undertaking a general medical
rotation. He then trained in oncology in Cardiff and Cambridge, becoming a consultant in Bristol in 1994. He has
sessional commitments to Southmead Hospital in Bristol and attends the Taunton Nuffield Hospital. His major clinical
interests are gastro-intestinal malignancies (oesophagus, stomach, pancreas, colo-rectal). Interest in lung cancer and clinical
research was stimulated as a MRC Clinical Scientist in Norman Bleehens’ Unit in Cambridge where the MRC cancer trials
unit was situated at the time. A MD related to lung cancer and scheduling of topoisomerase poisons with and without
radiation is the basis of on-going interest in chemo-radiation interactions. He has a major interest in research and where
possible all patients who are referred will be offered an appropriate clinical trial. Until recently a challenging clinical load
has seen up to 1000 new patients with cancer annually, but now is spending more time as Clinical Director of the West
of England Local Research network whose job is to fund the NHS costs of delivering research activity in the NHS. He is
also a member of the NCRI upper GI studies group and chair of the pancreas cancer sub group. He is a member of the
editorial board of the journal Clinical Oncology, and an author in more than 45 publications.
UPPER GI
Dr Richard Turkington (Day One & Day Two)
Senior Lecturer in Medical Oncology, Queens University Belfast
The future role of personalised medicine in operable oesophageal cancer.
Dr Richard Turkington is a Clinical Senior Lecturer in Medical Oncology at the Centre for Cancer Research and Cell
Biology, Queen’s University Belfast and an Honorary Consultant at the Northern Ireland Cancer Centre with an interest
in oesophago-gastric cancer. Having graduated in medicine from Queen’s University Belfast he began specialty training
in Medical Oncology in 2005. In 2007 he was awarded a Cancer Research UK Booby Moore Clinical Research
Fellowship to pursue a PhD in novel drug target discovery in colo-rectal cancer under the supervision of Professor Patrick
Johnston. Following completion of his Phd Dr Turkington was appointed as an Academic Clinical Lecturer in the field
of oesophago-gastric cancer and in 2013 he became a Visiting Research Fellow at the Hutchison/MRC Cancer Unit,
University of Cambridge, under the supervision of Professor Rebecca Fitzgerald. His work has been published in high
impact journals and in 2014 he received the American Society of Clinical Oncology Merit Award. Dr Turkington’s principle
research interests include oesophago-gastric cancer and the analysis of genomic datasets for the discovery of biomarkers
and mechanisms of resistance to chemotherapeutic agents. These discoveries are being translated into clinical advances
through the implementation of biomarker-led clinical trials. As part of the oesophago-gastric cancer team at Queen’s
University Belfast Dr Turkington is seeking to transform the care of oesophago-gastric patients through the integration of
laboratory discoveries, translational science and clinical research.
Mr Andrew Davies (Day Two)
Consultant Upper GI surgeon at Guy’s and St Thomas’ NHS Foundation Trust
“Surgery for Oesophageal cancer in the 21st Century: Current Practice and
future developments”
BSc (hons) MBChB MSc MD FRCS Andrew Davies is a Consultant surgeon at Guy’s & St Thomas’ Oesophago-gastric
centre and Senior lecturer at King’s College, London. St Thomas’ is a high volume unit specializing in oesophago-gastric
cancer surgery and complex upper GI reconstruction. The unit research programme, which Mr. Davies leads, contributes a
database of nearly 1,000 oesophagectomy patients towards numerous international research collaborations, including the
forthcoming TNM 8 international staging system for oesophageal cancer. Mr. Davies has a particular interest in minimally
invasive surgery, and during his training was awarded a prestigious laparoscopic surgery fellowship to Pittsburg, USA,
where Prof J Luketich heads the world’s largest thoracoscopic oesophageal cancer unit. Other clinical interests include the
staging and individualized management of oesophageal cancer, the subject of his MD thesis.
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
CLOSING KEYNOTE SPEAKER
Professor Anthony Zietman
Massachesetts General Hospital and Harvard Medical School
“Beams, Dreams and Proton schemes – how the UK can avoid the mistakes of
US cancer care”
Professor Zietman received his undergraduate training at Oxford University in the UK and then went to medical school at
the Middlesex Hospital, London University graduating in 1983. After residencies in internal medicine and clinical oncology
he moved to the Massachusetts General Hospital in Boston, USA for a fellowship in radiation biology. Since joining the
staff he has authored over 200 original articles and reviews on many aspects of GU cancer. His particular research
interests are in the specific roles of active surveillance, brachytherapy, hormone therapy, and proton beam therapy in the
treatment of prostate cancer. He also has a long-standing interest in the organ-sparing management of bladder cancer.
He is currently the Jenot and William Shipley Professor of Radiation Oncology at Harvard Medical School, Editor-in-Chief
of the International Journal of Radiation Oncology, Biology, Physics, Trustee of the American Board of Radiology, and the
former President and Chair of the American Society for Radiation Oncology (ASTRO)
We are leading the
way in clinical
homecare. Since 1992
our highly skilled
clinical teams have
cared for millions
of people living
with a wide range of
conditions. What’s
more we are the UK’s
leading provider
of home anti-cancer
treatments, helping
people get the
treatment they need,
in the place they
most want to be.
hah.co.uk
there’s a better place to get better
Find out
more at
Stand #2
39887 HAH Oncology Forum HP ad v5 AW.indd 1
03/05/2016 12:38
Improving experience
through cancer treatment
Improved efficacy of 5-FU by mixing?
Mucodis® Oral* has 4 key actions to help in
the prevention/treatment of oral mucositis
1
TS-substrate
2
5-FU
metabolite
3
thymidylate synthetase (TS)
Disodium levofolinate for use in combination
with 5-fluorouracil in cytotoxic therapy
Information about this product, including adverse reactions, precautions,
contra-indications and method of use can be found at www.medac-uk.
co.uk Prescribers are recommended to consult the summary of product
characteristics before prescribing. Legal classification: POM. Further
information is available from medac GmbH, Scion House, Stirling University
Innovation Park, Stirling FK9 4NF T: 01786 458086 E: [email protected]
Adverse events should be reported. Reporting forms
and information can be found at www.mhra.gov.uk/
yellowcard. Adverse events should also be reported
to medac drug safety at: [email protected]
4
Prevention of oral mucositis
Relief of dry mouth
2
1
3
(Mucodis® Mouthwash and Mucodis®
Oromucosal Spray)
Pain relief
1
3
4
(Mucodis® Mouthwash and Mucodis®
Oromucosal Spray)
Healing of lesions
1
3
4
(Mucodis® Mouthwash and Mucodis®
Oromucosal Spray)
References
1. Colonis. Mucodis® Mouthwash Instructions for Use. 2015
2. Cirillo, N. et al. A hyaluronic acid-based compound inhibits fibroblast senescence induced by oxidative stress in vitro and
prevents oral mucositis in vivo. J Cell Physiol. 2015: 230(7); 1421-1429
3. Colonis. Mucodis® Oromucosal Spray Instructions for Use. 2015
4. Colella, G. et al. Efficacy of a spray compound containing a pool of collagen precursor synthetic amino acids (L-Proline,
L-Leucine, L-Lysine and Glycine) combined with sodium hyaluronate to manage chemo/radiotherapy-induced oral
mucositis. Int J Immunopathol Pharmacol. 2010: 23(1): 143-151
* 'Mucodis® Oral' refers collectively to Mucodis® Mouthwash and Mucodis® Oromucosal Spray
Date of Preparation: May 2016
Promotional Code: UK-CPL-241-2016-052-V1
medac code: 020/04/2016
Date of preparation: April 2016
1
(Mucodis® Mouthwash)
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
NOTES
NOTES
UK Oncology Forum 2016 • Thursday 16th June & Friday 17th June 2016 • Beaumont House, Windsor
Secretariat
Athena Meetings & Events
Beechfield House
Winterton Way
Macclesfield
Cheshire
SK11 0LP
Contact Name Direct Line Email
Website:
Lisa Young
+44 (0) 1625 509187
[email protected]
www.athenameetings.com
The programme has been designed and developed solely by the Oncology Forum Faculty. No sponsors have any input or influence over the programme.
This meeting is for UK Oncology Healthcare Professionals only. The meeting will run strictly in accordance to the ABPI Code of Practice.
The varying sponsorships packages are primarily for the purchase of promotional exhibition stand space.